Principal component analysis of flow-volume curves in COPDGene to link spirometry with phenotypes of COPD.

Publisher: BioMed Central Ltd Country of Publication: England NLM ID: 101090633 Publication Model: Electronic Cited Medium: Internet ISSN: 1465-993X (Electronic) Linking ISSN: 14659921 NLM ISO Abbreviation: Respir Res Subsets: MEDLINE

Publication: 2001- : London : BioMed Central Ltd.
Original Publication: London : Current Science Ltd., c2000-

Pulmonary Disease, Chronic Obstructive*/diagnosis ; Pulmonary Disease, Chronic Obstructive*/genetics ; Pulmonary Emphysema* ; Emphysema*; Humans ; Principal Component Analysis ; Smoking ; Spirometry ; Phenotype ; Forced Expiratory Volume

Background: Parameters from maximal expiratory flow-volume curves (MEFVC) have been linked to CT-based parameters of COPD. However, the association between MEFVC shape and phenotypes like emphysema, small airways disease (SAD) and bronchial wall thickening (BWT) has not been investigated.
Research Question: We analyzed if the shape of MEFVC can be linked to CT-determined emphysema, SAD and BWT in a large cohort of COPDGene participants.
Study Design and Methods: In the COPDGene cohort, we used principal component analysis (PCA) to extract patterns from MEFVC shape and performed multiple linear regression to assess the association of these patterns with CT parameters over the COPD spectrum, in mild and moderate-severe COPD.
Results: Over the entire spectrum, in mild and moderate-severe COPD, principal components of MEFVC were important predictors for the continuous CT parameters. Their contribution to the prediction of emphysema diminished when classical pulmonary function test parameters were added. For SAD, the components remained very strong predictors. The adjusted R ² was higher in moderate-severe COPD, while in mild COPD, the adjusted R ² for all CT outcomes was low; 0.28 for emphysema, 0.21 for SAD and 0.19 for BWT.
Interpretation: The shape of the maximal expiratory flow-volume curve as analyzed with PCA is not an appropriate screening tool for early disease phenotypes identified by CT scan. However, it contributes to assessing emphysema and SAD in moderate-severe COPD.
(© 2023. The Author(s).)

Int J Chron Obstruct Pulmon Dis. 2019 Feb 14;14:409-418. (PMID: 30863041)
N Engl J Med. 1978 Jun 8;298(23):1277-81. (PMID: 651978)
Respir Res. 2013 Nov 19;14:131. (PMID: 24251975)
Sci Rep. 2018 Nov 30;8(1):17484. (PMID: 30504791)
Eur Respir J. 2005 Aug;26(2):319-38. (PMID: 16055882)
Respir Med. 2017 Feb;123:48-55. (PMID: 28137496)
Ann Am Thorac Soc. 2018 Oct;15(10):1186-1196. (PMID: 30011374)
Nervenarzt. 1998 Nov;69(11):968-74. (PMID: 9859118)
JAMA Intern Med. 2015 Sep;175(9):1539-49. (PMID: 26098755)
Respir Med. 2019 Sep;156:58-68. (PMID: 31437649)
Ann Am Thorac Soc. 2019 Aug;16(8):982-989. (PMID: 30865842)
Am J Med. 1972 Jun;52(6):725-37. (PMID: 5030170)
Chronic Obstr Pulm Dis. 2019 Jul 24;6(3):256-266. (PMID: 31342731)
Lancet Respir Med. 2018 Aug;6(8):591-602. (PMID: 30072106)
Respir Physiol Neurobiol. 2016 Jun 15;227:69. (PMID: 26687468)
N Engl J Med. 2019 Sep 26;381(13):1257-1266. (PMID: 31553837)
J Clin Invest. 1951 Nov;30(11):1175-90. (PMID: 14888695)
Nat Med. 2012 Nov;18(11):1711-5. (PMID: 23042237)
Am J Respir Crit Care Med. 1999 Jan;159(1):179-87. (PMID: 9872837)
N Engl J Med. 1970 Jun 4;282(23):1318-9. (PMID: 5442364)
Sci Rep. 2019 Sep 11;9(1):13159. (PMID: 31511572)
Lancet. 2016 Apr 30;387(10030):1817-26. (PMID: 27203508)
Chest. 2013 May;143(5):1436-1443. (PMID: 23648907)
COPD. 2010 Feb;7(1):32-43. (PMID: 20214461)
Eur Respir J. 2012 Dec;40(6):1324-43. (PMID: 22743675)
Chest. 1976 Jan;69(1):51-5. (PMID: 1244288)
Respir Physiol Neurobiol. 2015 Dec;219:30-5. (PMID: 26275685)

11N3922N Fonds Wetenschappelijk Onderzoek; R01-089897 United States NH NIH HHS

Keywords: COPD; Computed tomography; Maximal expiratory flow-volume curve; Principal component analysis

Date Created: 20230119 Date Completed: 20230123 Latest Revision: 20230123

20231215

PMC9854102

10.1186/s12931-023-02318-4

36658542